MASSIVE BIO at #ASCO24

REVOLUTIONIZING CANCER CARE with AI-POWERED CLINICAL TRIAL MATCHING

At #ASCO24, Massive Bio is set to unveil Massive Bio Clinical Network, an innovative AI platform that is redefining how cancer patients and physicians connect with clinical trials. This groundbreaking technology is designed to accelerate research and development, improve patient care, and ultimately transform the landscape of oncology.

Problems with Clinical Trials
Physicians face many challenges in referring their patients to clinical trials, including limited awareness of active clinical trials, evaluating their patients' eligibility, time constraints, and logistical barriers. Research indicates that these issues lead to under-enrollment of eligible patients and over-referral of ineligible patients. Massive Bio Clinical Network makes it easier for physicians to refer patients to the right clinical trials by removing these barriers using AI-powered software and Massive Bio's free concierge services for patients.

Find the Right Trial, Faster
Using Massive Bio Clinical Network, physicians have access up-to-date information on actively recruiting cancer clinical trials. Physicians can find the right trial options and evaluate eligibility criteria easily according to their patient's cancer diagnosis, biomarkers, treatment history and location. Physicians can also easily identify trial sites close to their patients.

AI Enabled Co-Pilot
With Dr. Arturo AI as their co-pilot, physicians can interactively summarize their patient's disease, identify potentially eligible trials and refer them in minutes using speech or text.

The Power of Multi-Trial Matching
Massive Bio's pre-screening and matching process systematically ensures accurate identification of all cancer trials for which patients are potentially eligible, increasing the chances of referrals to the right trials.

Concierge Services
Through Massive Bio Clinical Network, referred patients can take advantage of concierge services. Patient relations coordinators engage patients to answer their questions and understand their current condition, and oncology nurses help patients navigate the last mile in the clinical trial enrollment process.

Discover More!

#ASCO24 POSTER

Precision Cancer Consortium to Explore an Innovative and Efficient Multi-Trial Matching Method with Massive Bio

• Clinical research teams manually screen patients for cancer trials, a process that can take ~25 minutes per single trial using highly specialized resources, restricting trial options available to patients, and negatively impacting enrollment rates.
• Precision Cancer Consortium, including seven of the top 20 pharmaceutical companies, collaborated with Massive Bio to explore an innovative and efficient multi-trial matching method.
• This initiative focused on shifting towards a multi-trial prescreening approach, incorporating NGS testing results, and using artificial intelligence to enhance accuracy and efficiency of trial matching, particularly for targeted therapies.

Explore Results!

WHO IS MASSIVE BIO?

Massive Bio helps cancer patients around the world gain access to clinical trials of innovative new oncology treatments that can help create better outcomes. Our mission is to help all cancer patients in need, regardless of where they live or their financial circumstances.

Find More Clinical Trial Options with Massive Bio

Massive Bio Clinical Network, powered by artificial intelligence, precisely matches patients to clinical trials based on their diagnostics, geographical location, treatment history, and other critical parameters, such as biomarker status. We deliver a dedicated Clinical Trial Matching Service support within 3 hours after receiving your patients' medical records. And we support him or her from start to finish, while keeping you informed at every step and ensuring that your patient receives the best treatment option of their trial.

MASSIVE BIO'S GLOBAL IMPACT

"At Massive Bio, our mission transcends traditional clinical boundaries, harnessing our AI-driven expertise to connect patients with potentially life-saving treatments. With our unwavering commitment to cancer research, we empower oncologists, patients, and trials with the insights and efficiencies needed to accelerate R&D and enhance patient care, ensuring that every cancer patient has access to the trials they need, when they need them."